drugset / Trial / NCT03360630
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
Phase 1/2
Completed
60 enrolled
Capital Medical University
Duke University · collabGeneplus-Beijing Co. Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.
Timeline
- Start
- 2016-11-01
- Primary completion
- 2022-12-31
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-CIK | Cell therapy | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 100 mg | — |